Eynav Klechevsky, Ph.D.

Assistant Professor
Pathology and Immunology

Immunology Program
Cancer Biology Program
Molecular Microbiology and Microbial Pathogenesis Program
Computational and Systems Biology Program

Research Abstract:

The ability to distinguish between physiological and pathogenic antigens and to make decisions
about how to respond to particular pathogens or a disease condition signifies a properly functioning adaptive immune system. Dendritic cells (DCs), a diverse family of antigen presenting cells, are required to explain how these specific responses are initiated and controlled. Our work on the immune system is focused on the biology of DCs in humans. Using cellular and molecular techniques we are examining the specializations that make DC subsets so adept at detecting inflammatory signals, and driving different modules of acquired immune responses. The role that individual DC subsets provide in directing adaptive immunity is also critical to our understanding human disease, and guides us in identifying new principles and practices that would hopefully lead to new treatments for some of
the challenging human diseases.

Selected Publications:

For a complete list of our publication please visit:


Human dendritic cells - stars in the skin.Klechevsky E. Eur J Immunol. 2013

Human dendritic cells subsets as targets and vectors for therapy. Klechevsky E, Banchereau J. Ann N Y Acad Sci. 2013 May;1284:24-30.

Banchereau J, Zurawski S, Thompson-Snipes L, Blanck JP, Clayton S, Munk A, Cao Y, Wang Z, Khandelwal S, Hu J, McCoy WH 4th, Palucka KA, Reiter Y, Fremont DH, Zurawski G, Colonna M, Shaw AS, Klechevsky E. Immunoglobulin-like transcript receptors on human dermal CD14+ dendritic cells act as a CD8-antagonist to control cytotoxic T cell priming. Proc Natl Acad Sci U S A. 2012 Oct 29.

Banchereau J, Thompson-Snipes L, Zurawski S, Blanck JP, Cao Y, Clayton S, Gorvel JP, Zurawski G, Klechevsky E. The differential production of cytokines by human Langerhans cells and dermal CD14(+) DCs controls CTL priming.Blood. 2012 Jun 14;119(24):5742-9.

Ueno H, Klechevsky E, Schmitt N, Ni L, Flamar AL, Zurawski S, Zurawski G, Palucka K, Banchereau J, Oh S. Targeting human dendritic cell subsets for improved vaccines. Semin Immunol. 2011 Feb;23(1):21-7.

Klechevsky E, Flamar AL, Cao Y, Blanck JP, Liu M, O`Bar A, Agouna-Deciat O, Klucar P, Thompson-Snipes L, Zurawski S, Reiter Y, Palucka AK, Zurawski G, Banchereau J. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood. 2010 Sep 9;116(10):1685-97.

Ueno H, Schmitt N, Klechevsky E, Pedroza-Gonzalez A, Matsui T, Zurawski G, Oh S, Fay J, Pascual V, Banchereau J, Palucka K. Harnessing human dendritic cell subsets for medicine. Immunol Rev. 2010 Mar;234(1):199-212.

Banchereau J, Klechevsky E, Schmitt N, Morita R, Palucka K, Ueno H. Harnessing human dendritic cell subsets to design novel vaccines. Ann N Y Acad Sci. 2009 Sep;1174:24-32.

Klechevsky E, Liu M, Morita R, Banchereau R, Thompson-Snipes L, Palucka AK, Ueno H, Banchereau J. Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines. Hum Immunol. 2009 May;70(5):281-8.

Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, Thompson-Snipes L, Briere F, Chaussabel D, Zurawski G, Palucka AK, Reiter Y, Banchereau J, Ueno H. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity. 2008 Sep 19;29(3):497-510.

Banchereau J, Ueno H, Dhodapkar M, Connolly J, Finholt JP, Klechevsky E, Blanck JP, Johnston DA, Palucka AK, Fay J. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon.J Immunother. 2005 Sep-Oct;28(5):505-16.

Klechevsky E, Kato H, Sponaas AM. Dendritic cells star in Vancouver. J Exp Med. 2005 Jul 4;202(1):5-10.

Last Updated: 3/23/2021 1:24:46 PM

Back To Top

Follow us: